Core Viewpoint - The stock of Wangshan Wangshui-B (02630) surged over 14%, reaching a new high of 112.7 HKD, following the announcement of significant research findings related to the antiviral drug VV116 against Nipah virus [1] Company Summary - Wangshan Wangshui was established in 2013, focusing on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - The company announced a licensing and collaboration agreement with Ascletis Pharma in December, granting exclusive rights for the development, manufacturing, and commercialization of VV116 for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections in Greater China [1] Industry Summary - Recent research published by the Wuhan Institute of Virology confirmed that the oral nucleoside drug VV116 has significant antiviral activity against the Nipah virus, providing new hope for the prevention and treatment of this highly fatal emerging infectious disease [1] - The findings suggest that VV116 could serve as a preventive medication for high-risk groups such as healthcare workers and laboratory personnel, offering a ready option for addressing current and future Nipah virus outbreaks [1]

Core Viewpoint - The stock of Wangshan Wangshui-B (2630.HK) surged nearly 15% to reach a historical high of HKD 112.7, with a market capitalization exceeding HKD 18.9 billion, following the announcement of significant research on the oral nucleoside drug VV116 for treating Nipah virus infection [1][2]. Group 1: Company Developments - Wangshan Wangshui Biopharmaceutical Co., Ltd. has collaborated with researchers from the Wuhan Institute of Virology and the Shanghai Institute of Materia Medica to publish important findings on VV116, demonstrating its significant antiviral activity against the Nipah virus [1]. - The research indicates that VV116 could serve as a preventive medication for high-risk groups such as healthcare workers and laboratory personnel, providing a ready option for addressing current and future Nipah virus outbreaks [1]. Group 2: Product Information - The oral nucleoside drug VV116 was developed collaboratively by the Shanghai Institute of Materia Medica and Junshi Biosciences, with ownership held by Shanghai Wangshi Biopharmaceutical Technology Co., Ltd. and production entrusted to Shanghai Diseno Biopharmaceutical Co., Ltd. [2]. - Wangshi Biopharmaceutical is a joint subsidiary of Junshi Biosciences' subsidiary Shanghai Juntao Biopharmaceutical Technology Co., Ltd. and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. [2].

Core Viewpoint - The stock of Wangshan Wangshui-B (02630) surged over 14%, reaching a new high of 112.7 HKD, following the announcement of significant research findings regarding the antiviral drug VV116 against Nipah virus [1] Company Summary - Wangshan Wangshui was established in 2013, focusing on three therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - The company announced a licensing and collaboration agreement with Ascletis Pharma in December, granting exclusive rights for the development, manufacturing, and commercialization of VV116 for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections in Greater China [1] Industry Summary - Recent research published by the Wuhan Institute of Virology confirmed that the oral nucleoside drug VV116 has significant antiviral activity against the Nipah virus, providing new hope for the prevention and treatment of this highly fatal emerging infectious disease [1] - The findings suggest that VV116 could serve as a preventive medication for high-risk groups such as healthcare workers and laboratory personnel, as well as a ready drug option for current and future Nipah virus outbreaks [1]

格隆汇1月21日丨ST华西（维权）(002630.SZ)公布，公司于2026年1月21日召开第六届董事会第二十一 次会议, 通过了《关于聘任公司董事会秘书的议案》。经公司董事长提名，董事会提名委员会任职资格 审查通过，公司董事会同意聘任吴胜峰为公司董事会秘书，任期从本次董事会审议通过之日起至第六届 董事会任期届满。公司董事长黄有全先生不再代行董事会秘书职责。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 蘇州旺山旺水生物醫藥股份有限公司（「本公司」） 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02630 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 66,677,133 | RMB | | 1 | RMB | | 66,677,133 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 66,677,133 | RMB | | 1 | RMB | | 66,677,133 | | 2. 股 ...

Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock Code 股份代號: 2630) 22 December 2025 Dear non-registered shareholder(s), 各位非登記股東： Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into ef ...

Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 (a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） (Stock Code 股份代號: 2630) Dear registered shareholder(s), 22 December 2025 Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic diss ...

每经AI快讯，旺山旺水-B(02630.HK)午后拉升逾15%，截至发稿涨14.81%，报88港元，成交额1333.12 万港元。 ...

Core Viewpoint - The stock of 旺山旺水-B (02630) surged over 15% in the afternoon, reaching a price of 88 HKD, with a trading volume of 13.33 million HKD, following the announcement of a licensing agreement with 先声药业 for the new indication of VV116 [1] Group 1: Licensing Agreement - 旺山旺水 has entered into a licensing agreement with 先声药业, granting the latter exclusive rights to the use of hydrogen bromide dextromethorphan suspension for treating respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections in the Greater China region [1] - This collaboration aims to leverage the strengths of both companies in research, production, and commercialization to accelerate the clinical development and commercialization of VV116, ultimately benefiting more patients [1] Group 2: Company Pipeline and Focus Areas - 旺山旺水 is focused on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - As of October 21, 2025, the company has established a diversified pipeline of nine innovative products, with two in the commercialization stage, four in clinical stages, and three in preclinical stages [1] - In addition to its innovative drug pipeline, 旺山旺水 is also involved in the generic drug sector, with three products either commercialized or nearing commercialization [1] - The company's two core products are LV232 and TPN171 [1]

Core Viewpoint - The stock of Wangshan Wangshui-B (02630) surged over 15% following the announcement of a licensing agreement with Sihuan Pharmaceutical for the new indication of VV116, aimed at treating RSV and HMPV infections in Greater China [1] Group 1: Company Developments - Wangshan Wangshui has entered into a licensing agreement with Sihuan Pharmaceutical, granting exclusive rights for the use of dextromethorphan hydrobromide in treating RSV and HMPV infections in Greater China [1] - The collaboration aims to leverage the strengths of both companies in research, production, and commercialization to accelerate the clinical development and commercialization of VV116 [1] Group 2: Product Pipeline - As of October 21, 2025, Wangshan Wangshui has established a diversified pipeline of 9 innovative products, with 2 in the commercialization stage, 4 in clinical stages, and 3 in preclinical stages [1] - The company also has a generic drug segment, with 3 products either commercialized or nearing commercialization [1] - The two core products of Wangshan Wangshui are LV232 and TPN171 [1]